Eye cancer treatment depends on the type, size, and location of the tumor, but most cases are managed with some combination of radiation, laser therapy, chemotherapy, or surgery. The goal in nearly every case is to destroy the cancer while preserving as much vision as possible. When the tumor is caught early and remains localized, the five-year survival rate for ocular melanoma (the most common eye cancer in adults) is 88%. That drops to 19% once the cancer has spread to distant parts of the body.
Radiation Therapy
Radiation is the most common treatment for medium-sized eye tumors, particularly uveal melanoma, which forms in the colored part of the eye or the tissue layer beneath the retina. There are two main approaches.
Plaque brachytherapy involves surgically stitching a small, coin-shaped radioactive disc directly onto the wall of the eye, right over the tumor. The plaque stays in place for several days, delivering a concentrated dose of radiation to the cancer before a surgeon removes it. Because the radiation travels only a short distance, it targets the tumor while limiting damage to surrounding tissue.
Proton beam therapy uses a focused external beam of protons aimed precisely at the tumor. It is especially useful for tumors near the optic nerve or other sensitive structures. Five-year tumor control rates with proton beam therapy reach about 96%, meaning the cancer stays under control in the vast majority of patients. Vision loss can still occur over time as a side effect, but proton therapy’s precision helps reduce collateral damage compared to conventional radiation.
Laser and Heat-Based Treatments
For very small tumors, typically 2 to 3 millimeters thick and located toward the back of the eye, doctors can use a technique called transpupillary thermotherapy. A focused infrared laser delivers heat through the pupil directly onto the tumor, destroying it without cutting into the eye. This approach works best for tumors caught at a very early stage or as a supplement to radiation for slightly larger ones.
Cryotherapy uses extreme cold instead of heat. A probe applied to the outside of the eye freezes and kills small tumors, particularly those on or near the surface. It is more commonly used in retinoblastoma, the childhood eye cancer, for small tumors that remain near the front of the retina.
Chemotherapy for Retinoblastoma
Retinoblastoma is the most common eye cancer in children, usually diagnosed before age five. Treatment has shifted dramatically in recent years toward delivering chemotherapy directly to the eye rather than through the whole body.
In intra-arterial chemotherapy, a catheter is threaded from the groin up to the tiny artery that supplies blood to the eye. Chemotherapy drugs are released directly into the eye’s blood supply, bathing the tumor in a high concentration of medication while keeping the dose in the rest of the body very low. A 2018 study from Memorial Sloan Kettering covering 452 eyes treated over roughly a decade found a 96% eye salvage rate with this technique. Even among children with advanced tumors (classified as Group D, meaning extensive disease inside the eye), 88% of eyes were saved.
For tumors that have seeded into the gel-like fluid inside the eye, doctors can inject chemotherapy directly into the eye’s interior. This intravitreal injection targets floating tumor cells that other methods might miss.
Immunotherapy for Metastatic Uveal Melanoma
When uveal melanoma spreads beyond the eye, typically to the liver, treatment options were historically very limited. That changed with the approval of tebentafusp, the first immunotherapy drug to show a clear survival benefit in this cancer. It works as a bispecific protein: one end latches onto a marker found abundantly on melanoma cells, while the other end grabs and activates T cells, pulling them close enough to attack. In clinical trials, patients receiving tebentafusp had a median overall survival of 21.7 months compared to 16 months for those on other treatments. That five-month improvement was a meaningful step for a cancer that had long resisted immunotherapy.
Tebentafusp only works in patients whose immune system carries a specific genetic marker (HLA-A*02:01), which is present in roughly half of the general population. For those who don’t qualify, clinical trials continue to explore other options.
Chemotherapy for Intraocular Lymphoma
Primary intraocular lymphoma is a rare cancer that forms in the fluid or tissue inside the eye. Treatment typically involves injecting methotrexate, a chemotherapy drug, directly into the eye. The injection schedule is intensive at first: weekly treatments for the initial several weeks, then gradually tapering to every two weeks and eventually once a month. The full course of treatment often stretches close to a year. Because the drug goes directly into the eye, side effects outside the eye are minimal compared to whole-body chemotherapy.
Surgery: Tumor Removal and Enucleation
Some small tumors can be surgically cut out of the eye in a procedure called local resection. This is relatively uncommon because radiation achieves similar results for most tumors without the surgical risks of opening the eye.
When a tumor is very large, has caused severe damage, or has not responded to other treatments, the entire eye may need to be removed in a surgery called enucleation. During the procedure, a smooth implant is placed in the eye socket to maintain its shape. Recovery takes one to two months. Around six to eight weeks after surgery, once the socket has healed, you meet with an ocularist, a technical artist who designs, paints, and fits a custom prosthetic eye. Modern prosthetics are remarkably realistic and move naturally with the remaining eye muscles.
Losing an eye affects depth perception and peripheral vision on that side, and it takes time to adjust. Most people adapt well over several months, learning to compensate by turning their head slightly to cover the blind spot.
How Treatment Decisions Are Made
The treatment you receive depends on several overlapping factors: the type of eye cancer, the tumor’s size and exact location inside the eye, whether it has spread, and your overall health. For uveal melanoma, small tumors often get laser therapy or radiation. Medium tumors are typically treated with plaque brachytherapy or proton beam therapy. Large tumors that threaten vision entirely or have outgrown radiation’s reach may require enucleation. For retinoblastoma in children, the priority is saving both life and sight, so doctors lean heavily on targeted chemotherapy delivered through the artery or directly into the eye before considering removal.
Many patients receive a combination of treatments. A tumor might be treated with radiation first, followed by laser therapy to clean up residual cancer cells. Or chemotherapy might shrink a large retinoblastoma enough to make laser treatment or cryotherapy effective. Treatment plans are typically developed by a team that includes an ocular oncologist, a radiation specialist, and sometimes a medical oncologist if the cancer has spread beyond the eye.